Can a liver shunt boost immunotherapy in cancer patients?
NCT ID NCT07365930
First seen Jan 30, 2026 · Last updated May 12, 2026 · Updated 22 times
Summary
This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It tests whether adding a procedure called TIPS (which creates a small channel in the liver to reduce pressure) can help keep the liver working longer. About 350 participants will be followed to see if TIPS improves liver function, survival, and quality of life in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital of Düsseldorf
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.